What's in Regenexx, LLC's pipeline?

Regenexx, LLC has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Regenexx, LLC's portfolio?

Top competitors by shared drug class: Anterogen Co., Ltd., Hospital for Special Surgery, New York, Istituto Ortopedico Rizzoli.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/regenexx-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Regenexx, LLC — Portfolio Competitive Intelligence Brief

Regenexx, LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Regenexx SD® procedure	Regenexx SD® procedure	phase 3	Autologous stem cell therapy		Orthopedics / Regenerative Medicine

Therapeutic area mix

Orthopedics / Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Anterogen Co., Ltd. · 1 shared drug class
Hospital for Special Surgery, New York · 1 shared drug class
Istituto Ortopedico Rizzoli · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Regenexx, LLC:

Cite this brief

Drug Landscape (2026). Regenexx, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/regenexx-llc. Accessed 2026-05-15.